Nanobots Therapeutics develops the MotionTx platform, which utilizes nanobot technology to enhance the penetration of therapeutic agents into tissues and improve drug accumulation in target cells. This approach addresses the challenge of insufficient drug delivery in oncology, potentially transforming treatment outcomes for various diseases.
Funding
$610K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BFounders
Product
Problem
Current methods of delivering therapeutic agents to target cells often suffer from insufficient penetration into tissues, limiting drug accumulation and reducing treatment efficacy, particularly in oncology. This challenge hinders the effective treatment of various diseases where targeted drug delivery is crucial.
Solution
Nanobots Therapeutics is developing the MotionTx platform, a technology designed to enhance the penetration of therapeutic agents into tissues and improve drug accumulation within target cells. MotionTx utilizes nanobots to carry drugs, maximizing local routes of administration and enabling the development of novel therapeutics with improved tissue penetration capabilities. This platform aims to overcome the limitations of traditional drug delivery methods, potentially transforming treatment outcomes across a range of therapeutic indications. The technology is based on research led by Prof. Samuel Sánchez.
Target Audience
The primary target audience includes patients with diseases requiring improved drug delivery, particularly in oncology, and pharmaceutical companies seeking innovative drug delivery platforms.
Features
- MotionTx platform facilitates enhanced drug accumulation in target cells.
- Nanobots enable superior tissue penetration for improved therapeutic efficacy.
- Platform can carry a variety of drugs for different therapeutic indications.
- Maximizes local routes of administration for targeted delivery.
- NBT-101 targets bladder cancer.
- NBT-102 targets an undisclosed indication.